Blue Cross Blue Shield of Michigan Drops Wegovy and Others Blue Cross Blue Shield of Michigan (BCBS MI), the states largest nonprofit insurer covering over 4.5 million members, recently announced it will stop covering three major GLP-1 medications Wegovy , Zepbound , and Saxenda for fully insured large groups, effective January 2025
Weight Management Board-certified physician supporting medical weight loss alongside the behavioral and appetite factors that drive it
Wegovy (semaglutide) is a once-a-week injection thats approved by the Food and Drug Administration (FDA) to: Reduce excess body weight and maintain weight reduction in: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher who also have weight-related medical problems, such as high cholesterol or high blood pressure Adolescents ages 1217 who are at or above the 95th percentile on sex- and age-specific growth charts Reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or higher Wegovy belongs to a family of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists)
Horcajada-Molteni M-N, Chanteranne B, Lebecque P, et al
This weekly dosing schedule allows semaglutide to maintain consistent blood levels over seven days, activating GLP-1 receptors continuously without the inconvenience of daily pills or injections